Capital Insight Partners’s Pacira BioSciences PCRX Stock Holding History

Capital Insight Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-47,190	Closed	-$1.82M	–	168
2022 Q4	$1.82M	Sell	47,190 -7,776	-14%	-$378K	0.47%	66
2022 Q3	$2.92M	Sell	54,966 -936	-2%	-$52K	0.79%	41
2022 Q2	$3.26M	Buy	55,902 +1,367	+3%	+$89.5K	0.76%	43
2022 Q1	$4.16M	Sell	54,535 -209	-0.4%	-$13.9K	0.85%	34
2021 Q4	$3.29M	Buy	54,744 +1,537	+3%	+$84.7K	0.67%	52
2021 Q3	$2.98M	Buy	53,207 +22,646	+74%	+$1.31M	0.65%	57
2021 Q2	$1.85M	Buy	30,561 +8,520	+39%	+$539K	0.42%	90
2021 Q1	$1.54M	Buy	+22,041	New	+$1.57M	0.38%	99

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Capital Insight Partners's PCRX Position: Q1 2023 in Review

Capital Insight Partners sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 47,190 shares — an estimated $1.82M sold.

Capital Insight Partners first reported a position in PCRX in Q1 2021 and held it in 8 quarters. The position peaked at $4.16M in Q1 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Capital Insight Partners reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Capital Insight Partners sold 47,190 Pacira BioSciences shares in Q1 2023, an estimated $1.82M.
Capital Insight Partners first reported a position in Pacira BioSciences in Q1 2021 and held it in 8 quarters.
Capital Insight Partners's Pacira BioSciences position peaked at $4.16M in Q1 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Capital Insight Partners's 13F filing for Q1 2023, filed 28 Apr 2023.